cyrilzakka/clinical-trials huggingface dataset:
NICE: NeuroImaging in Cessation Education

The investigators aim to examine the effect on smoking cessation rate by showing stroke patients who are active smokers images of their strokes.

The investigators hypothesize that showing actual images of a patient's stroke to the participant on either brain CT or MRI will be a similarly easy to understand quantification of damage done to the participant's body. Given the link between smoking and stroke risk, the investigators believe that providing this imaging in addition to standard smoking cessation education may improve rates of smoking cessation after stroke. If this proves true, addition of a patient's neuroimaging to standard post-stroke smoking cessation education would be an easy method to improve smoking cessation rates in stroke patients, at minimal cost.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥18
* Active smoker, as defined: at least 100 cigarettes in their entire life, must have smoked cigarette at least once in 4 days prior to onset of stroke
* Primary ischemic or hemorrhagic stroke identified on neuroimaging (MRI DWI/ADC or CT of brain)
* Onset of stroke symptoms within 30 days to time of recruitment
* Capacity to comprehend counseling data: Each participant will be given a cognitive screening test to assess the ability to comprehend and accurately answer the medical history questionnaire (MMSE). If the participant fails this test (score \< 23), they will be excluded.
* Patients discharged home or short term rehab with expectation of returning home within the study period

Exclusion Criteria:

* Patients whose stroke deficits clinically prevent them from reasonably being physically able to continue to smoke, such as bilateral upper extremity paresis, tracheostomy, GCS ≥9
* Patients with sensory aphasia that impairs comprehension
* Subarachnoid hemorrhage
* Transient ischemic attack
* Other cause of cerebral ischemia or hemorrhage not defined as primary ischemic or hemorrhagic stroke (i.e. hemorrhagic metastases)
* Patients whose stroke symptoms started \>30 days from time of enrollment
* Patients discharged to acute rehab, long term acute care hospital or hospice who are unlikely to have access to cigarettes
* Patients unable to complete cognitive screening test for whom an appropriate proxy does not exist
* Patients who do not speak fluent English (given that the study largely revolves around oral education on smoking cessation, clear communication between participant and coordinator must be possible)
Impact of Auditory Stimulation in Eating Pleasure (EDERE 2021)

Background. Decreased taste and smell contribute to loss of appetite (anorexia), and the resulting protein-energy malnutrition increases the frailty of the elderly. The risk of falls, disability, infections and depression often requires them to be institutionalized. Elderly, undernourished and toothless patients often complain about the monotony of a soft, mixed-texture diet. In a previous study, some participants highlighted the pleasure of crunching cookies that have a solid texture that can be eaten in any dental condition. However, the age-related decrease in hearing (presbyacusis) is frequent and progressive from the age of 60. The hypothesis of this work is that older patients may perceive a crunchy food crunching in their mouth, despite presbycusis. If the hypothesis is verified, this would make geriatric caregivers aware of the possibility of diversifying the texture of food, in order to stimulate the pleasure of eating and increase the dietary intake in this population of patients who are often undernourished, dysphagic, edentulous and hearing impaired. The originality of this study is to share the expertise of geriatricians and specialists in mastication/swallowing (dental surgeon, speech-language pathologist), hearing (ENT doctor, hearing care professional) and nutrition (dietician).

Type of study. Type of study MR-004 "Research not involving the human person". Protocol. Compare the noise and pleasure of crunching between two hyperprotein nutritional supplements: a soft filled cookie (Nutra Cake™, Délical, France) and a crunchy cookie of the Breton type (Protibis™, Solidages, France). Blind study impossible: each subject will eat a cookie then the other in a random order and will be his own control. The tests will be performed without the possible hearing aids, but with or without the dentures according to the patient's preference. Indeed, some patients have dental prostheses that are no longer suitable for chewing, and that they wear only for aesthetics. Objective. Validate the evaluation criteria "Do you hear the biscuit crunch?" and "Is it a pleasure?" If so, encourage diversification with crunchy foods with a suitable texture, as well as dental and prosthetic rehabilitation of dependent elderly people.


Eligibility Criteria:
Inclusion Criteria:

Subjects 65 years of age or older, hospitalized in geriatrics or EHPAD residents.

Exclusion Criteria:

risk of false route when eating cookies, allergy to an ingredient in cookies
A Study of GW685698X 100mcg Administered Once Daily Either in the Morning or the Evening and GW685698X 250mcg Administered Once Daily in the Evening Via DISKHALER for 28 Days in Subjects With Persistent Bronchial Asthma.

The purpose of this study is to compare the efficacy and safety of GW685698X 100mcg once daily either in the morning or the evening and GW685698X 250mcg administered once daily in the evening via DISKHALER for 28 days in subjects with persistent bronchial asthma.


Eligibility Criteria:
Inclusion Criteria:

* Outpatients aged between 16- 65 years.
* Male and female; female subjects must be non-child bearing potential or of childbearing potenetial with negative pregnancy test and willing to use acceptable contraceptive methods
* Documented clinical history of persistent asthma first diagnosed at least 6 months prior to Visit 1
* Currently receiving inhaled short-acting beta-2 agonists for symptom relief
* A lung function of between 50 to 90% predicted (PEF)
* Increase in PEF of at least15%, 20 minutes after inhalation of 400mcg salbutamol

Exclusion Criteria:

* History of respiratory tract infection and/or exacerbation of asthma within a period of 4 weeks prior to Visit 1
* History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnoea, respiratory arrest or hypoxia seizures.
* A history of two or more asthma exacerbations requiring treatment with oral corticosteroids or hospitalisation in the 6 months before Visit 1.
* Past or present disease that, as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, haematologic disease, neurological disease, endocrine disease or pulmonary disease (including, but not confined to, chronic bronchitis, emphysema, bronchiectasis with the need of treatment, cystic fibrosis and bronchopulmonary dysplasia).
* Known or suspected sensitivity to corticosteroids, VENTOLIN, or the constituents of ROTADISKS (e.g., lactose).
* Undergoing allergen desensitisation therapy.
* Neurological or psychiatric disease or history of drug or alcohol abuse that would interfere with the subject's proper completion of the protocol requirements.
* Is a current smoker or has a smoking history of 10 pack years or more (e.g., 20 cigarettes/day for 10 years). Note: Current smoker is defined as currently smoking or stopped smoking within 6 months of screening visit.
Combination of Cryosurgery and NK Immunotherapy for Tumors in Transplanted Liver

The aim of this study is the safety and efficacy of cryosurgery plus natural killer(NK) immunotherapy to tumors in transplanted liver.

By enrolling patients with tumors in transplanted liver adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using cryosurgery and NK cells.

The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).

Eligibility Criteria:
Inclusion Criteria:

* All standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies after cancer recurrence
* Body tumor 1-6, the maximum tumor length \< 5 cm
* KPS ≥ 70, lifespan \> 6 months
* Platelet count ≥ 80×109/L，white blood cell count ≥ 3×109/L, neutrophil count ≥ 2×109/L, hemoglobin ≥ 80 g/L

Exclusion Criteria:

* Patients with cardiac pacemaker
* Patients with brain metastasis
* Patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction
Non Traumatic Neuro-Vascular Diseases Critical Complications : a Prospective Cohort Study

The purpose of this observational epidemiological study is to investigate the management and the complications associated with Non Traumatic Neuro-Vascular Diseases. Data will be analysed to answer pre-defined scientific projects and to improve management of these conditions.

Anonymous data will be collected by study coordinators in a secured e-database. Cross audit will be performed to check data.

Eligibility Criteria:
Inclusion Criteria:

* Non Traumatic Neuro-Vascular Diseases

Exclusion Criteria:

* Consent withdrawal
Interventional Trial of Vitamin D Deficiency in the Patients of General Departments

The purpose of the study is to examine the vitamin D state of elder patients in therapeutic departments and to compere the treatment during the hospitalization with the out-patient treatment.

Today vitamin D is thought to be one of the most important vitamins in the human body. It's made in the skin during the sun expose, so it must be sufficient in so sunny countries as Israel. Although many old people in our country suffer from vitamin d deficiency which bring them to recurrent falls, osteoporotic fractures and physical disability. This problem is still underestimated by health authorities in different countries.

In this study we will examine the vitamin D state of the therapeutic patient older than 65 year including their physical self-estimation, muscle strength measurement and gait-and-balance tests. Then, according to the resent studies, we will treat the patients in the interventional group with two large doses of vitamin D during a month. After that we will compere their health and physical state with the patients treated in the out-hospital department.

So we will try to find a useful approach to treat the vitamin D deficiency during the hospitalization.

Eligibility Criteria:
Inclusion Criteria:

* the patient was admitted to a general department of Rambam Medical Center for any reason from March to May 2008
* the patient is 65 years old or older
* the patient is in a good health, based on medical history, physical examination and laboratory screening evaluation.

Exclusion Criteria:

* renal failure with creatinine level more then 1.3 mg/dL or nephritic syndrome.
* liver disease with transaminase rise three times from normal level.
* nephrolithiasis in the last fife years.
* primary hyperparathyroidism, hypoparathyroidism or pseudohypoparathyroidism.
* advanced cancer.
* chronic diarrhea or malabsorption.
* granulomatous disease (sarcoidosis, tuberculosis, lymphoma).
* patients, who are receiving barbiturates, rifampin, anticonvulsants.
* patients, who are receiving digitalis.
* patients, who are receiving glucocorticoids for more than two weeks during the study.
* advanced dementia.
Prevalence of Gastric Inlet Patches of the Cervical Esophagus.

As known from several observational and retrospective endoscopic studies the prevalence of gastric inlet patches (GIPs) of the cervical esophagus is estimated between 1-10%. In most cases GIPs are found within endoscopy as an incident finding, since in most cases they are harmless and do not cause any symptoms. None the less several data exist where an association between GIPs and globus sensations is discussed. Case reports even refer to bleeding complications and moreover to malignant transformations of GIPs.

As a result of the assumed association of GIPs and globus sensations we performed a pilot trial. Here we included 10 patients with globus and GIPs and were able to demonstrate a significant symptom relief after ablation of the GIP (Meining et al, Endoscopy 2006). To exclude a potential placebo-effect we concluded a multicenter and sham controlled trial where we imposingly were able to prove the symptom relief after ablation of the GIPs (Bajbouj et al, Gastroenterology 2009).

All patients, who are scheduled for esophagogastroduodenoscopy (EGD) in any of the above mentioned endoscopical departments are routinely standardized asked whether they have any hints suggestive for globus sensations (modified globus-questionnaire from Deary et al., J Psychosom Res 1995). Concurrently it is noted, whether the patients have endoscopical detected GIP. All GIPs are biopsied and examined in one institute. Together with anamnestic data (age, gender) a talley sheet gives a survey of all relevant information to prove or disprove following hypotheses.

Study hypotheses:

1. The presence of GIPs is associated with globus sensations. In other words: Do patients with globus sensations significantly more often have GIPs?
2. GIPs are not congenital, they arise in the course of the time and become symptomatic. In other words: Do GIPs significantly occur in more elderly people?
3. The more increased the GIPs diameter is the more likely globus sensations are present? In other words: Do huge GIPs cause significantly more often symptoms than small ones?
4. The more mucus-producing mucosa is histologically proven the more likely globus sensations are present? In other words: Do we find more cardiac mucosa in patients with symptoms than fundus mucosa?


Eligibility Criteria:
Exclusion Criteria:

* emergency EGD
* any condition which contraindicates biopsy sampling
* unavailable informed consent for the GD
End Of Life in the Critically Ill patiEnt

The purpose of this multicentric study is to evaluate the perception of the quality of the end of life in intensive care units seen from the side of the caregivers, trough the CAESAR scale.

More than 20% of deaths occur in hospital after a stay in intensive care units; up to half of them happens as result of a treatment limitation. Ensuring end-of-life quality is important, not only because is a moral duty of all caregivers, but also to prevent negative effects in close relatives of dead patients.

In an assessment of quality of in-hospital deaths involving 3793 patients, only 35% of the deaths were judged to be of acceptable quality by the nurses.

Assessment tools have been developed recently on this topic. Most studies have focused on the perception of end-of-life quality by close relatives, particularly through the CAESAR scale in the most recent one.

The main purpose of this multicentric study is to evaluate the perception of the quality of the end-of-life in intensive care units seen from the side of the caregivers, in relation to the new French legislative framework.

Eligibility Criteria:
Inclusion Criteria:

* Caregivers of intensive care unit whose patient has recently deceased

Exclusion Criteria:

* Refusal of participation by caregivers
* Refusal of participation by family of deceased patient
* Patient in cardiac arrest at the time of ICU admission.
* Age of deceased patient was under 18 years
* Patient in brain death
The Relationship of Platelet Counts With Sickle Cell Anemia in the Eastern Region of Saudi Arabia

This study aims to evaluate the relationship between platelet counts and sickle cell disease in the eastern region of the Kingdom of Saudi Arabia.

Introduction:

This study aims to evaluate the relationship between platelet counts and sickle cell disease in the eastern region of the Kingdom of Saudi Arabia.

Purpose: This study aims to assess the prevalence and factors associated with elevated platelet counts in people with sickle cell disease in the eastern region of Saudi Arabia.

Methods: This cross-sectional study at Majmaah University will analyze prerecorded data frfom the eastern region of Saudi Arabia to investigate the relationship between platelet counts and sickle cell disease, identifying associated factors and assessing the link .

Importance: To assess the relationship between platelet counts and disease severity in Pationt with SCD.

Aim :To investigate the relationship between platelet counts and SCD in the eastern region of the Kingdom of Saudi Arabia.

Eligibility Criteria:
Inclusion criteria: All the diagnosed patients of sickle cell disease regardless of age and gender.

Exclusion criteria: Patients without having sickle cell disease regardless of age and gender.
Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/

A study in mild/moderate IPF patients using an αVβ6 PET ligand to evaluate target engagement.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of IPF, within 5 years prior to Screening,
* FVC %predicted ≥45%; historical FVC for entry in the study is permitted if within 1 month of screening.
* DLco (hemoglobin-adjusted) ≥30%; historical DLco for entry in the study is permitted if within 1 month of screening.
* Participants receiving treatment for IPF with nintedanib or pirfenidone are allowed,if on a stable dose for at least 3 months

Exclusion Criteria:

* Currently receiving or planning to initiate treatment for IPF (fibrosis) with agents not approved for that indication by the FDA
* Forced expiratory volume during the first seconds of the forced breath (FEV1)/FVC ratio \<0.7
* Clinical evidence of active infection, including but not limited to bronchitis, pneumonia, sinusitis that can affect FVC measurement or IPF progression
* Known acute IPF exacerbation or suspicion by the Investigator of such, within 6 months of Screening
* Smoking of any kind within 3 months of Screening
Prostate Boost Irradiation With Stereotactic Body RT (SBRT)

A randomized controlled open-label trial in patients with high risk prostate cancer. Eligible and consenting patients will be randomly allocated to receive stereotactic body radiotherapy (SBRT) boost to prostate or conventional radiotherapy boost to prostate in 1:1 ratio. Prostate radiotherapy boost will be administered after standard pelvic radiotherapy. Subjects will be followed for 24 months post radiation treatment for Quality of Life assessment and toxicity.

In this study we investigate stereotactic body radiotherapy (SBRT) as a boost radiotherapy treatment, following pelvic radiotherapy, in patients with high risk prostate cancer (PrCa) treated with Androgen Deprivation Therapy (ADT). One hundred patients with localized high risk PrCa will receive ADT for a total of 3 years. Three months after initiation of ADT all patients will receive pelvic (lymph node and prostate) treatment of 45Gy in 25 fractions (5 days per week). Then patients will be randomized to receive either The conventional radiotherapy (CRT) of 33 - 35 Gy in 16 fractions (5 days per week - over 22 days) (comparator arm) or SBRT boost treatment of 19.5 - 21 Gy in three fractions (1 treatment per week - over 22days) (experimental arm). SBRT boost treatment will be delivered with either cyberknife or VMAT technique.

Eligibility Criteria:
Inclusion Criteria:

* Histological and or clinical diagnosis of high risk adenocarcinoma of the prostate within six months of entry (stage T3 or higher and/or Gleason score 8 or higher and/or initial PSA level above 20;)
* No radiographic evidence of metastatic disease to the abdomen, lymph nodes, bone or other distant organs; determined by standard staging investigations (bone scan and CT-scan of the abdomen and pelvis) or incidental findings (localized N0, M0 disease)
* Patient is able to complete the quality of life questionnaires in English.
* Informed consent obtained

Exclusion Criteria:

* • Histological diagnosis of carcinoma of the prostate more than six months prior to potential registration date;
* Previous treatment for carcinoma of the prostate (other than biopsy or TURP), including bilateral orchiectomy;
* Patients previously on more than twelve weeks of hormone therapy for their PrCa;
* Past history of other malignancies except: adequately treated non-melanoma skin cancer or other solid tumours curatively treated with no evidence of disease for more than 3 years;
* Contraindications to placement of gold seeds for daily prostate localization;
* Previous pelvic RT and/or significant pelvic surgery;
* Severe diverticular or inflammatory bowel disease (as determined by the treated radiation oncologist)
* Previous hip replacement
* PSA over 50
* IPSS 20 or higher
* TRUS-based prostate
* volume of \> 80 cc
Excision Versus Preservation of Spermatic Cord Lipoma Detected During Subinguinal Varicocelectomy

In the current study, the adult infertile patients with clinical varicoceles will be included. the patients will undergo subinguinal varicocelectomy. The patients with spermatic cord lipoma detected at the time of surgery will be enrolled and divided into 2 groups( excision group, group A and preservation group (B). semen parameters will be compared in both group at 3 and 6 months after surgery

This will be a prospective randomized study, in which adult infertile patients with clinical varicocele and oligo-athenospermia admitted to Urology department Tanta university hospital will be included and then the patients with detected spermatic cord lipoma at the time surgery will be enrolled and divided into 2 groups:

GROUP A : will undergo subinguinal varicocelectomy with excision of spermatic cord lipoma GROUP B : will undergo subinguinal varicocelectomy with preservation of spermatic cord lipoma

Inclusion criteria:

* Adult infertile males
* Clinical varicocele
* oligo-asthenospermia

Exclusion criteria:

* Adolescent varicocele
* Recurrent varicocele
* Presence of inguinal hernia
* Azospermic patients

Eligibility Criteria:
Inclusion Criteria:

* Adult infertile males
* Clinical varicocele
* Semen analysis show oligo-athenospermia

Exclusion Criteria:

* Adolescent varicocele
* Recurrent varicocele
* Presence of inguinal hernia
* Azospermic patients
Study on Umorestat Hydrogen Sulfate Capsule in Patients With Locally Advanced/Metastatic Pancreatic Cancer

Based on the tolerability, safety and pharmacokinetics phase I/II clinical trials of ulimostat hydrochloride capsules (LH011) combined with gemcitabine hydrochloride (GEM) in locally advanced/metastatic pancreatic cancer patients, to determine pharmacokinetics, the biotransformation pathway and metabolite profile of ulimostat in patients with locally advanced/metastatic pancreatic cancer.

This study is a research on the pharmacokinetics and gene polymorphisms of ulimostat hydrochloride capsules in patients with locally advanced/metastatic pancreatic cancer. Aims to collect the "Phase I/II clinical trials of the tolerability, safety and pharmacokinetics of ulimostat capsules (LH011) combined with gemcitabine hydrochloride (GEM) in patients with locally advanced/metastatic pancreatic cancer" patient's peripheral blood sample to determine the structure of the metabolites of ulimostat in the biological samples and trough concentration and genotyping tests were performed on patients to investigate the correlation between gene polymorphisms of metabolic enzymes, transporters, target protein uPA and proteins expressed in upstream and downstream signaling pathways and blood drug concentration, efficacy, safety and tolerance of ulimostat.

Eligibility Criteria:
Inclusion Criteria:

* Successfully enrolled in a Phase I/II clinical study on the tolerability, safety and pharmacokinetics of Umorestat hydrogen Sulfate capsule (LH011) combined with gemcitabine hydrochloride (GEM) for patients with locally advanced/metastatic pancreatic cancer.
* Fully understand the purpose and requirements of this study and sign a written informed consent.
* Willing to provide blood samples.

Exclusion Criteria:

* Suffering from inflammatory bowel disease.
* The researcher considers it unsuitable to participate in this study.